Revenue
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Fulgent Genetics, Inc. (FLGT)
Price$19.56Cached quote
Net income
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $322.7M | $283.5M | $289.2M | $619.0M | $992.6M | $421.7M | $32.5M | $21.4M | $18.7M | $18.3M | $9.6M | $1.3M |
| Gross profit | $130.9M | $107.2M | $104.5M | $366.9M | $777.1M | $331.9M | $18.4M | $10.7M | $10.2M | $11.6M | $4.5M | $342,000 |
| Gross margin | 40.56% | 37.82% | 36.12% | 59.28% | 78.29% | 78.70% | 56.63% | 49.90% | 54.35% | 63.22% | 47.07% | 26.76% |
| Research & development | $53.9M | $48.8M | $41.4M | $28.9M | $24.2M | $11.6M | $6.5M | $5.5M | $4.2M | $3.6M | $4.4M | $521,000 |
| Operating expenses | $222.0M | $181.1M | $300.0M | $188.4M | $101.1M | $41.7M | $18.8M | $15.7M | $13.7M | $10.6M | $9.5M | $1.3M |
| Operating income | −$91.1M | −$73.9M | −$195.5M | $178.5M | $676.0M | $290.2M | −$428,000 | −$5.1M | −$3.5M | $918,000 | −$5.0M | −$990,000 |
| Operating margin | −28.23% | −26.08% | −67.61% | 28.84% | 68.10% | 68.80% | −1.32% | −23.75% | −18.59% | 5.02% | −52.34% | −77.46% |
| EBITDA | −$67.0M | −$49.0M | −$169.4M | $211.2M | $687.0M | $293.1M | $1.7M | −$2.9M | −$1.8M | $2.1M | −$4.4M | −$794,000 |
| EBITDA margin | −20.76% | −17.28% | −58.57% | 34.12% | 69.21% | 69.51% | 5.16% | −13.62% | −9.36% | 11.42% | −46.33% | −62.13% |
| Net income | −$60.5M | −$42.7M | −$167.8M | $143.4M | $507.4M | $214.3M | −$411,000 | −$5.6M | −$2.5M | −$5.3M | −$8.3M | −$4.3M |
| Net profit margin | −18.75% | −15.07% | −58.03% | 23.17% | 51.12% | 50.82% | −1.26% | −26.26% | −13.40% | −29.26% | −86.82% | −335.13% |
| Basic EPSper basic share | -$1.97 | -$1.41 | -$5.63 | $4.76 | — | — | — | — | — | — | — | — |
| Diluted EPSper diluted share | -$1.97 | -$1.41 | -$5.63 | $4.63 | — | — | — | — | — | — | — | — |
Owners
Reported shareholders
8.31%of listed shares
BlackRock, Inc.2.29M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
BlackRock, Inc. | 8.31%2.29M shares |
ACADIAN ASSET MANAGEMENT LLC | 3.70%1.02M shares |
Gao Hanlin | ≈3.60%990.37K shares |
VANGUARD CAPITAL MANAGEMENT LLC | 2.87%789.5K shares |
JACOBS LEVY EQUITY MANAGEMENT, INC | 2.84%782.12K shares |
JPMORGAN CHASE & CO | 2.75%756.56K shares |
Diametric Capital, LP | 2.54%697.78K shares |
AMERIPRISE FINANCIAL INC | 2.44%670.08K shares |
DIMENSIONAL FUND ADVISORS LP | 2.27%625.36K shares |
Xie Jian | ≈2.14%588.42K shares |
GEODE CAPITAL MANAGEMENT, LLC | 1.89%521.01K shares |
STATE STREET CORP | 1.81%498.67K shares |
Invenomic Capital Management LP | 1.81%498.29K shares |
TWO SIGMA INVESTMENTS, LP | 1.46%400.99K shares |
Kim Paul | ≈1.32%362.55K shares |
CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.28%350.99K shares |
MILLENNIUM MANAGEMENT LLC | 1.17%320.91K shares |
GOLDMAN SACHS GROUP INC | 1.12%307.94K shares |
D. E. Shaw & Co., Inc. | 1.06%292.01K shares |
HRT FINANCIAL LP | 0.83%229.44K shares |
Percentages use 27.52M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 2, 2026Form 4 | Xie JianPresident and COO | SellCommon Stock | 2.1K | $17.89 | $38.4K | 367.6K |
| Jun 2, 2026Form 4 | Gao HanlinChief Scientific Officer | SellCommon Stock | 1.7K | $17.89 | $30.2K | 990.4K |
| May 27, 2026Form 4 | Xie JianPresident and COO | SellCommon Stock | 1.2K | $17.60 | $21.1K | 369.8K |
| May 27, 2026Form 4 | Gao HanlinChief Scientific Officer | SellCommon Stock | 945 | $17.60 | $16.6K | 992.1K |
| Dec 2, 2025Form 4 | Xie JianPresident and COO | SellCommon Stock | 1.1K | $28.33 | $32.3K | 336.7K |